Natco Pharma Q3 FY26 Results: PAT ₹151.3 Cr, Revenue ₹647.3 Cr; Interim Dividend ₹1.50
Natco Pharma reported Q3 FY26 results with a net profit of ₹151.3 crore and revenue of ₹647.3 crore. For the nine months, profit was ₹1,149.50 crore on revenue of ₹3,339 crore. The company announced an interim dividend of ₹1.50 per share for FY26.
The results show year-on-year growth and a dividend payout, which are material for investors. However, the nine-month performance shows a decline in profit, tempering the overall impact.
The company reported an increase in net profit and revenue for the quarter compared to the previous year, and announced an interim dividend, all of which are positive indicators.
Natco Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a net profit of ₹151.3 crore for the third quarter, an increase from ₹132.4 crore in the corresponding quarter of the previous year. Revenue for the quarter stood at ₹647.30 crore, up from ₹475 crore in the same period last year.
For the nine-month period ended December 31, 2025, the company posted a net profit of ₹1,149.50 crore on a revenue of ₹3,339 crore. This compares to a net profit of ₹1,477.40 crore on a revenue of ₹3,208.50 crore for the same period last year.
The Board of Directors has approved an interim dividend of ₹1.50 per share of ₹2 each for the financial year 2025-26. The company has also published newspaper advertisements regarding these results and the notice of the record date for the payment of the 3rd interim dividend.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.